BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially expressed between healthy individuals and those with Friedreich’s ataxia will be featured in an oral presentation at the upcoming Gordon Research Conference on Mitochondria and Chloroplasts during the session on “Organelle Biology Translated into Medicine and Agriculture.” The conference will take place July 17 – 22, 2022 at Mount Snow in West Dover, Vermont.
Details on the presentation are shown below.
Identification of Differentially Expressed Genes in Friedreich’s Ataxia Patients
David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics
July 21, 2022
8:40 PM ET
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Chief Financial Officer